Cell Lysis News and Research

RSS

Jennerex and Green Cross report positive phase 2 JX-594 clinical trial for liver cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Green Cross Corporation, a leading company in the development, manufacturing, and commercialization of viral vaccines and other biological products, today reported positive clinical data from a Phase 2 trial evaluating JX-594 for liver cancer which was conducted in South Korea.

21 Apr 2011

Scientists develop new method to detect virus presence in cells

Scientists at the Naval Research Laboratory Center for Bio-Molecular Science and Engineering have developed a method to detect the presence of viruses in cells and to study their growth.

12 Apr 2011

Scarab Genomics, CellMed enter agreement for Clean Genome E. coli Technology

Scarab Genomics announced a strategic agreement today with CellMed AG, a BTG International group company, in which CellMed AG will use Scarab Genomics' Clean Genome E. coli Technology in a new product development in the life science field.

7 Apr 2011

New ‘nanotech’ weapon against drug-resistant superbugs

Scientists at the Institute of Bioengineering and Nanotechnology (IBN) and IBM Research – Almaden have developed the first biodegradable polymer nanoparticles to combat drug-resistant superbugs, such as Methicillin-Resistant Staphylococcus aureus (MRSA). These nanoparticles can selectively kill the bacteria without destroying healthy red blood cells, and being biodegradable, have great potential to treat infectious diseases in the body. This was reported today in the leading scientific journal, Nature Chemistry [(2011) DOI: 10.1038/nchem.1012].

3 Apr 2011

Covaris launches Bench-top SF220 Formulation Processing System

Covaris Incorporated today announced the introduction of the Bench-top SF220 High Performance Formulation Processing System.

25 Mar 2011

Scientist identifies natural signaling molecule that can prevent Hemophilia A

A scientist from The Scripps Research Institute has identified a new role for a natural signaling molecule in preventing blood clot formation. The molecule could become a target for the development of novel and cost-effective treatments for blood clotting diseases such as Hemophilia A.

1 Feb 2011

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Celgene International Sàrl (NASDAQ: CELG) announced that data evaluating combination therapy REVLIMID® (lenalidomide) and dexamethasone in patients with high-risk asymptomatic smoldering multiple myeloma were presented during the American Society of Hematology's annual meeting. The study reported REVLIMID and dexamethasone prolonged time to progression.

6 Dec 2010

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Celgene International Sàrl announced that clinical data from two investigational studies evaluating the use of REVLIMID (lenalidomide) either with rituximab or following a rituximab-containing regimen in patients with chronic lymphocytic leukaemia were presented at the 52nd American Society of Hematology annual meeting.

6 Dec 2010

3SBio acquires pegsiticase global rights from EnzymeRx for $6.25 million

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced that is has acquired worldwide rights of pegsiticase for all indications from EnzymeRx for a total consideration of US$6.25 million.

29 Nov 2010

Covaris enters co-marketing partnership with Illumina for DNA shearing technologies

Covaris Inc. today announced that it has signed a co-marketing agreement with Illumina, Inc. making Covaris DNA shearing technologies the recommended method of shearing with Illumina next-generation sequencing product lines, including HiSeq, HiScanSQ, and Genome Analyzer.

From Illumina, Inc. 29 Sep 2010

Scientists develop new therapy for treatment of skin, lung cancer

Scientists at the University of Granada have developed a new therapy for the treatment of skin and lung cancer. This therapy involves the use of a suicide coliphage-gene (gene E) that can induce death to cells transfected with it.. Their studies have demostrated that this technique is not only effective in vitro (using tumour cell cultures), but also in vivo through the use of experimental animals in which tumours were induced.

22 Sep 2010

Scientists create nanoscale coating to eradicate methicillin resistant bacteria

Building on an enzyme found in nature, researchers at Rensselaer Polytechnic Institute have created a nanoscale coating for surgical equipment, hospital walls, and other surfaces which safely eradicates methicillin resistant Staphylococcus aureus (MRSA), the bacteria responsible for antibiotic resistant infections.

17 Aug 2010

Life Technologies launches AutoMate Express Forensic DNA Extraction System

Life Technologies Corporation today announced the commercial availability of the Applied Biosystems AutoMate Express™ Forensic DNA Extraction System, which is designed to streamline sample preparation and improve downstream DNA profile quality. The system, designed and validated as part of the complete Applied Biosystems human identification workflow to provide optimal efficiency and data quality, has already been adopted by all 48 government forensic laboratories in Japan.

5 Aug 2010

SIR offers five-day course that covers all aspects of acute stroke management

Catheter Lysis of Thromboembolic Stroke -an intensive five-day course offered by the Society of Interventional Radiology Oct. 24-28 in Dallas, Texas-provides interventional radiologists, neurointerventionalists, vascular neurologists and fellows-in-training with the unique educational opportunity to review, observe and discuss all aspects of acute stroke management.

29 Jul 2010

EKOS receives $2.7M grant to develop product for treatment of ICH

EKOS Corporation announced today that they received a $2.7 million grant from the National Institutes of Health for the development of a product to provide therapy for intracerebral hemorrhagic stroke.

7 Jun 2010

Microscopic image sensor to speed up detection of tumors

To diagnose cancer reliably, doctors usually conduct a biopsy including tissue ana-lysis - which is a time-consuming process. A microscopic image sensor, fitted in an endoscope, is being developed for in vivo cancer diagnosis, to speed up the detection of tumors.

7 Jun 2010

BD Diagnostics receives 510(k) clearance to market GBS assay on BD MAX System

BD Diagnostics, a segment of BD, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market the BD MAX™ GBS Assay for Group B Streptococcus on the BD MAX System. The BD MAX System is a next-generation automated workstation for molecular testing designed to streamline workflow and offer full walkaway automation to accommodate varying workloads for maximum lab efficiency and flexibility.

From BD (Becton, Dickinson and Company) 3 Jun 2010

Experts address fundamental questions related to renal failure in ICU

Despite the fact that recent medical advances have allowed healthcare professionals to stabilize patients who would have otherwise died, many stabilized patients later develop organ system failure. In fact, acute renal failure is one of the biggest threats to critically ill patients: forty percent of patients with this condition die.

14 May 2010

CBC, Scarab Genomics form agreement to increase manufacturing yield of Solinex rhu-pGSN

Critical Biologics Corporation (CBC) and Scarab Genomics announced today a strategic agreement to substantially increase the manufacturing yield of CBC's lead therapeutic protein candidate, Solinex™, an intravenous formulation of recombinant human plasma gelsolin (rhu-pGSN).

30 Apr 2010

$EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout$

EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout

EnzymeRx, LLC, a clinical-stage biotechnology company, announced top line results from its first clinical trial of pegsitacase (formerly called Uricase‑PEG 20). Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the management of hyperuricemia associated with tumor lysis syndrome.

30 Apr 2010